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Revolutions, postulated that scientific progress proceeds
linearly until the accumulation of a sufficient weight of
evidence that the current paradigm is unable to accommo-
date forces the reexamination of underlying assumptions,
and a new paradigm must be established (1). Viewed
through this framework, stunning advances of past decades
in identification and quantification of obstructive coronary
artery disease (CAD) stenosis represent the success of the
traditional belief that this condition underlies essentially all
stable ischemic heart disease (SIHD) syndromes. However,
there are now many “loose ends” that challenge this preoc-
cupation equating obstructive stenosis with SIHD, suggest-
ing that it may be time to rethink this scientific paradigm.
See page 951
To this end, a timely opinion paper based on the proceed-
ings of a recent international conference appears in this issue
(2). The authors call for a revision of the widely held
premise that SIHD is equivalent to an obstructive coronary
artery stenosis caused by atherosclerosis (e.g., CAD). In this
regard, the authors are to be congratulated for tackling an
important clinical dilemma and identifying potential patho-
physiological mechanisms underlying symptoms and signs
of myocardial ischemia in the absence of an obstructive
stenosis. This work brings at least 2 important topics into
focus: 1) what causes SIHD; and 2) if this differs sufficiently
from the current paradigm, how to best initiate the needed
paradigm shift.
What Causes SIHD?
Decades of information from pathological studies have
established that atherosclerosis underlies SIHD in the
overwhelming majority of cases. However, this finding,
reinforced by coronary angiographic data from large trials/
registries, was assumed to mean a flow-limiting lesion in a
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the absence of obstructive CAD, management of patients with
angina and other findings of SIHD represents a considerable
challenge for which there is virtually no reliable evidence
base. The link between symptoms and an obstructive
stenosis is so ingrained that many physicians doubt that a
patient may have symptoms and/or signs of ischemia in the
absence of such a stenosis. Such patients are often labeled
“atypical” or having “false-positive results” at noninvasive
evaluation. However, long-term follow-up studies docu-
ment that such patients may have increased adverse event
rates, poor quality of life, and consume considerable health
care resources compared with those without evidence of
ischemia (3–6). Several recent large studies have also
documented increased mortality (3,4,7), underscoring the
need for a better understanding of the pathophysiology of
this entity to improve identification and treatment.
Evidence Against Flow-Limiting Stenosis as
the Reference Standard for the Presence of SIHD
We agree with the authors (2) that evidence against flow-
limiting stenosis as the sine qua non for IHD is accumu-
lating. Briefly, the majority of patients with symptoms (e.g.,
chronic angina) and/or signs of ischemia undergoing an-
giography have no flow-limiting coronary stenosis (3,5,8).
Even when an obstructive stenosis is documented, clinicians
recognize that there is often wide variability in symptoms
and effort tolerance, as well as variable ischemic responses to
stress testing, making lack of concordance the rule (9).
Furthermore, there is a high degree of scatter in the
relationship between stenosis severity and flow (10,11).
Conversely, reduced flow responses to a variety of stressors
in myocardial regions perfused by nonstenotic vessels have
been well documented (12). The highly variable clinical
outcome after apparently successful intervention for stenosis
relief is such that current meta-analyses fail to document
differences in outcomes comparing medical therapy with
percutaneous coronary intervention (13).
The “SIHD equals obstructive CAD” paradigm fails to
recognize many other mechanisms that may alter determi-
nants of myocardial oxygen supply-demand with the poten-
tial to result in ischemia (Table 1). For example, there is
evidence for microparticle embolization and/or microvascu-
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cular flow-limiting stenosis with long-term outcome conse-
quences (14,15). Dynamic obstruction of larger (e.g.,
coronary artery spasm) and/or smaller (e.g., microvascular
spasm) vessels, as a result of heightened smooth muscle
activation and/or endothelial dysfunction, are increasingly
documented to cause ischemia and lead to impaired out-
comes (15,16). Stiffening conduit vessels may modify deter-
minates of myocardial oxygen supply-demand to the same
extent as a flow-limiting stenosis (17,18). Even with similar
Proposed Classification for StableIschemic He rt Disease Syndrom sTable 1 P opo d Classification for StableIschemic Heart Disease Syndromes
Type Location of Defect Potential Mechanisms
Vascular
Coronary Macrovessels Flow-limiting stenosis (atherosclerosis)
Endothelial dysfunction (e.g., athero
RFs, some viruses)
Spasm (e.g., mostly athero RFs,
cocaine)
Muscle bridge
Inflammation (e.g., cardiac transplant,
collagen diseases such as SLE or
polyarthritis)
Aberrant origin
Dissection (e.g., pregnancy, chest
trauma, Marfan syndrome)
Microvessels Microvascular dysfunction (some athero
RFs)
Endothelial dysfunction (e.g., mostly
athero RFs)
Spasm (athero RFs, others?)
Inflammation (cardiac transplant,
collagen diseases such as SLE or
polyarthritis)
Microemboli (e.g., athero RFs, AF)
Capillary insufficiency (e.g., LVH)
?
Other vessels Capacitance vessels Increased stiffness (e.g., aging,
calcification, hypertension, CRI)
?
Nonvascular
Cardiomyocyte
Transcellular Oxygen transport (reduced diffusion
[e.g., infiltrate, amyloid])
Energy substrate (e.g., depleted FFA,
glucose)
?
Intracellular Oxygen transport (e.g., defective
myoglobin)
Energy substrate (e.g., depleted FFA,
glucose)
?
Mitochondria Mitochondrial dysfunction/adaptation
(e.g., ischemic injury and protection,
heart failure, diabetes, aging)
?
Adventitia Adipocytes ?
Matrix Mast cells Spasm, others?
Miscellaneous ? ?
Aberrant origin anomalous coronary artery origin (e.g., left coronary artery from the right sinus of
Valsalva), coronary dissection associated with trauma, Marfan syndrome; AF  atrial fibrillation;
athero RF  atherosclerosis risk condition (e.g., hypertension, dyslipidemia, dysglycemia, insulin
resistance, smoking, chronic renal insufficiency [CRI]); FFA free fatty acid; LVH left ventricular
hypertrophy; SLE  systemic lupus erythematosus; ?  unknown.ischemic injury, there is differential expression of cardiacbiomarkers (19). In addition, the cardiomyocyte and its
metabolism, barriers to oxygen transport, the matrix, etc.
may all be implicated either alone or in combination in the
same or different (e.g., hypertension, heart failure, diabetes)
patient subgroups.
However, we disagree with the authors’ attempt to
debunk the “direct” relationship between obstructive CAD
and IHD (2), rather than recognizing that there is, in fact,
a direct relationship, but that this relationship is not the
only pathway to myocardial ischemia. Thus, a more enlight-
ened position would be that obstruction does not always
imply presence of ischemia and absence of obstruction does
not always imply absence of ischemia. We agree there is
clearly a need to shift to a multifactorial model highlighting
causes and mechanisms in pathoanatomy involved in the
pathogenesis of myocardial ischemia (Table 1). Otherwise,
we risk being like the drunken man, searching for his lost
keys under the streetlight, simply because the light is better.
A new multifactorial model could open novel pathways to
the development of diagnostic and therapeutic approaches
well beyond the current focus on revascularization. This is
the essence of Kuhn’s scientific revolution: adoption of
different ways of thinking that promise new, better solutions
in the future.
Initiating Paradigm Shift
Regarding the Cause of SIHD
The first step is to recognize the growing evidence against
the unitary theory of flow-limiting stenosis as the prereq-
uisite for SIHD and to accept the need to readjust the
prevailing wisdom of myocardial ischemia. The conference
summary helped to raise the profile of this question and, in
doing so, call for a revision using “the Copernican” revolu-
tion metaphor. But in our opinion, that paradigm shift is
best initiated by gradual or stepwise call for change, begin-
ning with development of a new terminology (Table 1). The
focus of Marzilli et al. (2) on the cardiomyocyte is important
but does not further advance the field by suggesting a
taxonomy that would provide a platform for future research.
Whether we need to abandon the term IHD remains to be
seen, but we do need a lexicon that better encompasses the
breadth of causes for the mismatch between substrate
delivery and cellular requirements that result in myocardial
ischemia. We also need to eliminate the inevitable confu-
sion possible if the term IHD continues to be used in both
the “conventional” way (i.e., as meaning obstructive CAD),
as well as with a new definition.
What Are the Implications
of a Paradigm Shift for SIHD?
Clearly, the clinical and research implications need to be
better developed. Once freed from the constraints of equat-
ing an “obstructive stenosis” with SIHD and vice versa,
scientists and clinicians will be better able to recognize novel
processes. Unfortunately, all of the processes proposed by
11
1
1
1
1
1
1
1
1
959JACC Vol. 60, No. 11, 2012 Pepine and Douglas
September 11, 2012:957–9 Rethinking Stable Ischemic Heart Diseasethe opinion paper (e.g., inflammation, microvascular and
macrovascular dysfunction [either at the smooth muscle or
endothelial level or both], thrombosis, angiogenesis) are
well documented as part of the atherosclerosis (or athero-
thrombosis) disease process. Therefore, when dealing with a
vascular basis for SIHD, atherosclerosis (or its risk condi-
tions) remains the likely mechanism. Scientists and clini-
cians will also be better able to explore the novel role of
nonatherosclerotic mechanisms (Table 1). Taking the view
that atherosclerotic CAD means a flow-limiting stenosis
ignores other factors and unnecessarily, severely restricting
our inquiry. It also no longer fits the evidence.
Conclusions
Clearly, dyshomeostasis, particularly at the coronary vascu-
lar level, plays a critically important role in the occurrence of
symptoms and signs of ischemia (chronic angina and test
abnormalities). But in addition to flow-limiting stenosis,
many other mechanisms likely contribute to this very
complex syndrome. Recognizing that stable ischemic syn-
dromes do not necessarily require a flow-limiting stenosis in
a large coronary artery, and severe stenosis does not neces-
sarily cause all ischemic syndromes, advances our under-
standing of the disease process(es) underlying these syn-
dromes and ultimately will lead to improved diagnostic
approaches and therapies. The conference summary in this
issue (2) should be viewed as a start in the right direction
and perhaps a new era in IHD.
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